![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWDA9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--482abef3e38670d2aa0fd0764180ad01c2a56efa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Chimerix-revised.jpg)
Chimerix
Chimerix is developing orally bioavailable antiviral therapies for unmet medical needs in immunocompromised patient populations, including transplant and oncology, HIV and HBV.
Website
www.chimerix.comPartner
Wende HuttonInvestment
Series D